Standout Papers

Evaluating eligibility criteria of oncology trials using real-world data and AI 2021 2026 2022 2024155
  1. Evaluating eligibility criteria of oncology trials using real-world data and AI (2021)
    Ruishan Liu, Shemra Rizzo et al. Nature

Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
2 intermediate papers

Works of Brandon Arnieri being referenced

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
2018
382 Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancer
2014

Author Peers

Author Last Decade Papers Cites
Brandon Arnieri 134 168 87 111 10 458
Melissa D. Curtis 214 255 76 49 8 414
Ellie Siden 59 79 107 102 12 475
Melisa Tucker 297 350 118 70 13 549
Gwynn Ison 88 208 97 68 16 416
Andrae Vandross 78 102 67 89 18 529
Tracy Lively 120 141 248 69 17 570
Alastair Matheson 55 95 75 86 14 447
Travis Osterman 55 117 59 17 31 463
Tiago M. de Carvalho 271 287 24 24 14 515
Angela K. Green 73 166 90 28 22 486

All Works

Loading papers...

Rankless by CCL
2026